A half day dedicated to kinases in drug discovery organized by SciLifeLab DDD in collaboration with AstraZeneca.

Kinases continue to attract much attention in drug discovery. Since the first compounds were launched in 2001 the learning curve of how to tackle different challenges has been steep. At the symposium we hope to give a broad overview where the field stands today and the different approaches one can take in drug discovery when interacting with kinases.

In the late afternoon we will dive deeper into the details of data generation and data interpretation to learn and discuss different techniques that can be applied to increase the chance for success.

The meeting is believed to be valuable for researchers in the area of drug discovery like medicinal chemists, structural biologists, pharmacologists, protein scientists, toxicologists etc.

This is a hybrid event. Läs mer här.

Symposium Program

11.00  Light lunch

12.00  Welcome

Ylva Gravenfors, SciLifeLab Drug Discovery and Development platform

12.30 Strategies for the rational development of highly selective kinase inhibitors

Prof. Stefan Knapp, Pharmaceutical Chemistry, Frankfurt University, Germany

13.30 Kinase targeting using covalent and degrader modalities

Dr. Lyn Jones, Center Protein Degradation, Dana-Farber Cancer Institute, Boston, USA

14.30  Coffee

15.00 Development of kinase biochemical assays: Scrutinizing the system for a higher value

Dr. Vladimir O. Talibov, Sprint Bioscience, Stockholm, Sweden

15.30 Utilizing targeted and proteome wide Cellular Thermal Shift Assays (CETSA®) for   Kinase inhibitors

Dr. Laurence Arnold, Pelago Bioscience, Stockholm, Sweden

16.00 Different kinase panels: Pros, cons and translation

MSc. Jenny Viklund, Principal Scientist, AstraZeneca, Gothenburg, Sweden

16.30 – 17.00   Summarizing discussion

Register at scilifelab.se/event

Host:  Ylva Gravenfors, SciLifeLab DDD  ylva.gravenfors@scilifelab.se